Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
FXR452 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A14963 | 29154964 | J Hepatol | Lipotoxicity and the gut-liver axis in NASH pathogenesis. | 2017 | Details |
| A14976 | 29148806 | J Med Chem | Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). | 2017 | Details |
| A15078 | 29107284 | Mol Metab | Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. | 2017 | Details |
| A15083 | 29104811 | Liver Res | Bile acid metabolism and signaling in liver disease and therapy. | 2017 | Details |
| A15097 | 29098111 | Liver Res | Bile acid receptors link nutrient sensing to metabolic regulation. | 2017 | Details |
| A15163 | 29066462 | Am J Physiol Endocrinol Metab | Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. | 2017 | Details |
| A15288 | 28986308 | Biochim Biophys Acta Mol Basis Dis | n-3 Fatty acids combined with flavan-3-ols prevent steatosis and liver injury in a murine model of NAFLD. | 2017 | Details |
| A15292 | 28983452 | Curr Pharmacol Rep | Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15353 | 28951211 | Biochim Biophys Acta Mol Basis Dis | MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR. | 2017 | Details |
| A15463 | 28895119 | FEBS Lett | FXR controls CHOP expression in steatohepatitis. | 2017 | Details |
| A15501 | 28874313 | Gastroenterol Hepatol | New therapeutic perspectives in non-alcoholic steatohepatitis. | 2017 | Details |
| A15513 | 28867301 | Cell Metab | Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. | 2017 | Details |
| A15554 | 28845983 | J Med Chem | A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15624 | 28803504 | Expert Rev Clin Pharmacol | The pharmacological management of NAFLD in children and adolescents. | 2017 | Details |
| A15671 | 28774887 | Gut | Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. | 2017 | Details |
| A15716 | 28746779 | Liver Int | Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. | 2017 | Details |
| A15732 | 28739572 | Mol Pharmacol | Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor. | 2017 | Details |
| A15802 | 28702667 | Integr Biol (Camb) | Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development. | 2017 | Details |
| A15862 | 28677333 | Aliment Pharmacol Ther | Review article: new treatments in non-alcoholic fatty liver disease. | 2017 | Details |
| A16023 | 28605664 | J Nutr Biochem | Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats. | 2017 | Details |
| A16094 | 28573213 | ACS Cent Sci | Chemoproteomic Profiling of Bile Acid Interacting Proteins. | 2017 | Details |
| A16131 | 28546081 | Pharmacol Ther | Targeting nuclear receptors for the treatment of fatty liver disease. | 2017 | Details |
| A16267 | 28478385 | J Biol Chem | Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. | 2017 | Details |
| A16353 | 28442273 | Mol Aspects Med | The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | 2017 | Details |
| A16378 | 28428116 | Pharmacol Res | Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling. | 2017 | Details |
| A16414 | 28406477 | Cell Death Dis | miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. | 2017 | Details |
| A16449 | 28381740 | Intern Med | The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD). | 2017 | Details |
| A16499 | 28351695 | Chem Biol Interact | Antihyperlipidemic and hepatoprotective effects of Gardenin A in cellular and high fat diet fed rodent models. | 2017 | Details |
| A16680 | 28249275 | Dig Dis | Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease. | 2017 | Details |
| A16681 | 28249273 | Dig Dis | Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. | 2017 | Details |
| A16740 | 28214524 | Gastroenterology | Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16758 | 28202906 | Sci Rep | BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. | 2017 | Details |
| A16771 | 28190475 | Phytomedicine | Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor. | 2016 | Details |
| A16773 | 28187366 | J Nutr Biochem | A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice. | 2017 | Details |
| A16819 | 28153708 | Biochim Biophys Acta Mol Basis Dis | Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance. | 2017 | Details |
| A17004 | 28052626 | Liver Int | Therapies in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17047 | 28029021 | Endocrinol Metab (Seoul) | Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A17142 | 27960079 | Cancer Cell | Liver Cancer Checks in When Bile Acid Clocks Out. | 2016 | Details |
| A17161 | 27939613 | Toxicol In Vitro | Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. | 2016 | Details |
| A17256 | 27889186 | Cancer Cell | Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis. | 2016 | Details |
| A17435 | 27605663 | J Biol Chem | Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease. | 2016 | Details |
| A17471 | 27773935 | Acta Pharmacol Sin | Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation. | 2016 | Details |
| A17585 | 27733832 | Front Pharmacol | Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. | 2016 | Details |
| A17601 | 27723468 | J Nutr Biochem | Soy isoflavones (Glycine max) ameliorate hypertriglyceridemia and hepatic steatosis in high fat-fed ovariectomized Wistar rats (an experimental model of postmenopausal obesity). | 2016 | Details |
| A17625 | 27709009 | Acta Pharm Sin B | Fatty liver diseases, bile acids, and FXR. | 2016 | Details |
| A17641 | 27693527 | Life Sci | Effect of HFD/STZ on expression of genes involved in lipid, cholesterol and glucose metabolism in rats. | 2016 | Details |
| A17691 | 27655848 | Sci Transl Med | Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. | 2016 | Details |
| A17713 | 27639801 | Gastroenterology | An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. | 2016 | Details |
| A17923 | 27475255 | Biochim Biophys Acta | Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice. | 2016 | Details |
| A18027 | 27405060 | J Hepatol | Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. | 2016 | Details |
| A18164 | 27311796 | Food Chem Toxicol | NF-E2-related factor 2 deletion facilitates hepatic fatty acids metabolism disorder induced by high-fat diet via regulating related genes in mice. | 2016 | Details |
| A18233 | 27268696 | Bioorg Med Chem Lett | Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties. | 2016 | Details |
| A18341 | 27196572 | Gut | Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. | 2016 | Details |
| A18386 | 27170389 | Dig Dis | Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies. | 2016 | Details |
| A18399 | 27158393 | Am J Transl Res | Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). | 2016 | Details |
| A18463 | 27111464 | J Appl Microbiol | Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice. | 2016 | Details |
| A18468 | 27109453 | Diabetes Obes Metab | Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. | 2016 | Details |
| A18473 | 27105827 | Nutr J | Pathophysiological role of host microbiota in the development of obesity. | 2016 | Details |
| A18538 | 27063275 | Clin Liver Dis | Emerging Therapies for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A18642 | 27018382 | Biochem Biophys Res Commun | Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice. | 2016 | Details |
| A18762 | 26962021 | Biochim Biophys Acta | Nuclear receptors and nonalcoholic fatty liver disease. | 2016 | Details |
| A18840 | 26909306 | Mol Metab | Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism. | 2015 | Details |
| A18919 | 26870934 | Semin Liver Dis | Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A19029 | 26812075 | J Hepatol | Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. | 2016 | Details |
| A19143 | 26730275 | World J Hepatol | Management of non-alcoholic fatty liver disease in 2015. | 2015 | Details |
| A19259 | 26668692 | World J Hepatol | Bile acid receptors and nonalcoholic fatty liver disease. | 2015 | Details |
| A19282 | 26655953 | J Biol Chem | Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice. | 2015 | Details |
| A19328 | 26628836 | J Clin Exp Hepatol | Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. | 2015 | Details |
| A19340 | 26620317 | Sci Rep | Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease. | 2015 | Details |
| A19419 | 26579441 | Acta Pharm Sin B | Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. | 2015 | Details |
| A19758 | 26375281 | PLoS One | Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver. | 2015 | Details |
| A20094 | 26159280 | Dig Dis | Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. | 2015 | Details |
| A20168 | 26114083 | Curr Hepatol Rep | PATHOGENESIS OF HEPATOCELLULAR CARCINOMA DEVELOPMENT IN NON ALCOHOLIC FATTY LIVER DISEASE. | 2015 | Details |
| A20255 | 26061453 | J Med Food | Maltitol Prevents the Progression of Fatty Liver Degeneration in Mice Fed High-Fat Diets. | 2015 | Details |
| A20288 | 26045279 | Dig Dis | Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. | 2015 | Details |
| A20353 | 26019035 | Ann Hepatol | The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. | 2016 | Details |
| A20459 | 25948514 | Eur J Nutr | Modulation of cholesterol-related gene expression by ergosterol and ergosterol-enriched extracts obtained from Agaricus bisporus. | 2015 | Details |
| A20833 | 25705637 | Ann Transl Med | Recent advances in the development of farnesoid X receptor agonists. | 2015 | Details |
| A20845 | 25690590 | Curr Atheroscler Rep | FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. | 2015 | Details |
| A20959 | 25617503 | J Hepatol | Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. | 2015 | Details |
| A21051 | 25553772 | Expert Opin Drug Metab Toxicol | Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. | 2015 | Details |
| A21174 | 25500885 | J Clin Invest | Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. | 2014 | Details |
| A21175 | 25500875 | Acta Pharmacol Sin | Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. | 2014 | Details |
| A21343 | 25388536 | Curr Top Med Chem | Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities. | 2014 | Details |
| A21361 | 25376397 | Obesity (Silver Spring) | The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice. | 2014 | Details |
| A21412 | 25339829 | World J Gastroenterol | FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. | 2014 | Details |
| A21454 | 25309079 | World J Gastroenterol | Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. | 2014 | Details |
| A21645 | 25156247 | Liver Int | Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. | 2014 | Details |
| A21891 | 24976401 | Biochem Biophys Res Commun | NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease. | 2014 | Details |
| A22021 | 24875360 | Biochem Biophys Res Commun | Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. | 2014 | Details |
| A22052 | 24849447 | Nan Fang Yi Ke Da Xue Xue Bao | [Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism]. | 2014 | Details |
| A22102 | 24819989 | Steroids | Bile acids are nutrient signaling hormones. | 2014 | Details |
| A22113 | 24812009 | Toxicol Sci | Human receptor activation by aroclor 1260, a polychlorinated biphenyl mixture. | 2014 | Details |
| A22210 | 24747563 | Biochem Biophys Res Commun | Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. | 2014 | Details |
| A22471 | 24534255 | Toxicol Appl Pharmacol | PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. | 2014 | Details |
| A22533 | 24486698 | Mol Cell Endocrinol | Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. | 2014 | Details |
| A22561 | 24463129 | Nan Fang Yi Ke Da Xue Xue Bao | [Effects of farnesoid X receptor agonist on adiponectin and its receptors]. | 2014 | Details |
| A22750 | 24333182 | J Hepatol | Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. | 2013 | Details |
| A22833 | 24275089 | Food Chem Toxicol | Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. | 2013 | Details |
| A22907 | 24222091 | Semin Liver Dis | Bile acid-mediated control of liver triglycerides. | 2013 | Details |